Company intelligence / Profile preview
SAGEbio
United Statessagebio.tech ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
SAGEbio has developed a proprietary integrated platform enabling rapid discovery and manufacturing of pharmaceutical proteins. Their lead program involves a novel subunit-type vaccine for COVID‑19 currently advancing through clinical phases. The company leverages AI-driven optimization and GMP production capabilities to accelerate candidate selection and facilitate partnerships for further clinical development.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Subunit vaccinesMultispecific biologics (biopharmaceutical proteins)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on SAGEbio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAGEbio.